Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus.

Abstract

OBJECTIVE:

Accumulation of advanced glycation end products (AGEs) is associated with age- and diabetes-related disease. The aim of the present study is to investigate the effects of metformin or pioglitazone on serum pentosidine levels, a well-defined AGE, in type 2 diabetes.

RESEARCH DESIGN AND METHODS:

66 Japanese patients were enrolled in this 6 months open-label study. In the metformin (n=22), the pioglitazone (n=22), and the control (optimal diet therapy, sulfonylurea and/or insulin) groups (n=22), serum levels of HbA (1c) and pentosidine were measured at baseline and 6 months after each treatment.

RESULTS:

HbA (1c) and pentosidine levels were not different at baseline among 3 groups, and HbA(1c) was significantly decreased at 6 months in each group. In the metformin and the pioglitazone groups, serum pentosidine levels were significantly decreased at 6 months after treatments (p=0.039 and p=0.031, respectively). Percent changes in pentosidine levels in the metformin and the pioglitazone groups were significantly lower than that in the control group (p=0.012 and p=0.019, respectively).

CONCLUSION:

6 months treatments with metformin or pioglitazone in clinical doses decreased serum pentosidine levels which resulted in greater %change of serum pentosidine levels than the control group, suggesting that these agents may prevent the diabetic complications associated with AGEs accumulation.

• Authors: I Kanazawa, M Yamamoto, T Yamaguchi, T Sugimoto
• Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association (Exp Clin Endocrinol Diabetes) Vol. 119 Issue 6 Pg. 362-5 (Jun 2011) ISSN: 1439-3646 [Electronic] Germany
• PMID: 21472665 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Chemical References

• Glycated Hemoglobin A
• Glycation End Products, Advanced
• Hypoglycemic Agents
• Thiazolidinediones
• hemoglobin A1c protein, human
• Metformin
• Arginine
• pentosidine
• Lysine
• Pioglitazone

Topics

• Aged
• Arginine (analogs & derivatives, blood)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Female
• Glycated Hemoglobin (analysis)
• Glycation End Products, Advanced (blood)
• Humans
• Hypoglycemic Agents (pharmacology, therapeutic use)
• Lysine (analogs & derivatives, blood)
• Male
• Metformin (pharmacology, therapeutic use)
• Middle Aged
• Pioglitazone
• Thiazolidinediones (pharmacology, therapeutic use)
• Time Factors